Corcept Therapeutics (CORT) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue reached $157.2M, up from $146.8M year-over-year, with net income at $20.5M versus $27.8M last year, driven by record prescription growth despite early pharmacy fulfillment issues.

• Rapid growth in hypercortisolism patient identification and treatment, along with strong clinical data in oncology and neurology, is driving business expansion.

• The company continues to advance its pipeline, including the NDA for relacorilant in hypercortisolism (FDA action date December 30, 2025) and pivotal trials in ovarian cancer and ALS.

• Ongoing legal proceedings include patent and antitrust litigation with Teva and shareholder actions, with potential impacts on future operations.

• Cash-generating operating model and strong cash reserves support ongoing R&D and clinical programs.

Financial highlights

• Q1 2025 revenue was $157.2M, up 7% year-over-year; 2024 revenue reached $675M.

• Net income declined to $20.5M from $27.8M year-over-year; diluted EPS was $0.17, down from $0.25.

• Cash and investments totaled $570.8M as of March 31, 2025.

• Operating expenses rose due to higher R&D and SG&A, compressing operating margin.

• $43M of common stock repurchased in Q1 2025.

Outlook and guidance

• 2025 revenue guidance reiterated at $900M–$950M, with growth expected to accelerate in the second half, driven by commercial initiatives and clinical milestones.

• NDA submission for relacorilant in ovarian cancer planned for Q3 2025, with MAA shortly after.

• Management anticipates funding operations and R&D activities over the next 12 months and beyond without needing to raise additional funds.